Template:Oral hypoglycemics and insulin analogs: Difference between revisions
Appearance
Content deleted Content added
add Insulin degludec/insulin aspart |
Berchanhimez (talk | contribs) remove insulin combinations because they're listed twice |
||
Line 180: | Line 180: | ||
* [[Glimepiride/pioglitazone]] |
* [[Glimepiride/pioglitazone]] |
||
* [[Glimepiride/rosiglitazone]] |
* [[Glimepiride/rosiglitazone]] |
||
* [[Insulin degludec/insulin aspart]] |
|||
* [[Insulin degludec/liraglutide]] |
|||
* [[Insulin glargine/lixisenatide]] |
|||
* [[Linagliptin/empagliflozin]] |
* [[Linagliptin/empagliflozin]] |
||
* [[Linagliptin/metformin]] |
* [[Linagliptin/metformin]] |
Revision as of 03:01, 19 July 2020
This template's initial visibility currently defaults to autocollapse
, meaning that if there is another collapsible item on the page (a navbox, sidebar, or table with the collapsible attribute), it is hidden apart from its title bar; if not, it is fully visible.
To change this template's initial visibility, the |state=
parameter may be used:
{{Oral hypoglycemics and insulin analogs|state=collapsed}}
will show the template collapsed, i.e. hidden apart from its title bar.{{Oral hypoglycemics and insulin analogs|state=expanded}}
will show the template expanded, i.e. fully visible.